SSA
IRD

Schonfeld Strategic Advisors’s Opus Genetics IRD Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,000
Closed -$45K – 3087
2022
Q1 		$45K Buy
+14,000
New +$47.9K ﹤0.01% 2350

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schonfeld Strategic Advisors's IRD Position: Q2 2022 in Review

Schonfeld Strategic Advisors sold out of Opus Genetics (IRD) in Q2 2022, closing a stake of 14,000 shares — an estimated $45K sold.

Schonfeld Strategic Advisors first reported a position in IRD in Q1 2022 and held it in 1 quarter. The position peaked at $45K in Q1 2022. 38 funds tracked by Wall St. Rank hold IRD as of Q2 2022.

  • Schonfeld Strategic Advisors reported no remaining Opus Genetics position as of Q2 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 14,000 Opus Genetics shares in Q2 2022, an estimated $45K.
  • Schonfeld Strategic Advisors first reported a position in Opus Genetics in Q1 2022 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Opus Genetics position peaked at $45K in Q1 2022.
  • 38 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.